TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

NORLIQVA

AMLODIPINE BESYLATE Calcium Channel Antagonists
Cardiovascular Approved 2022-02-24
1
Indication
--
Phase 3 Trials
4
Years on Market

Details

Status
Prescription
First Approved
2022-02-24
Routes
ORAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: AMLODIPINE BESYLATE

NORLIQVA Approval History

Loading approval history...

What NORLIQVA Treats

4 indications

NORLIQVA is approved for 4 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypertension
  • Coronary Artery Disease
  • Chronic Stable Angina
  • Vasospastic Angina
Source: FDA Label

Drugs Similar to NORLIQVA

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

SDAMLO
AMLODIPINE BESYLATE
4 shared
BRILLIAN PHARMA
Shared indications:
HypertensionCoronary Artery DiseaseChronic Stable Angina +1 more
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM
AMLODIPINE BESYLATE
2 shared
Viatris
Shared indications:
HypertensionCoronary Artery Disease
AMLODIPINE BESYLATE AND VALSARTAN
AMLODIPINE BESYLATE
2 shared
ALEMBIC
Shared indications:
HypertensionCoronary Artery Disease
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE
AMLODIPINE BESYLATE
2 shared
STRIDES PHARMA INTL
Shared indications:
HypertensionCoronary Artery Disease
CADUET
AMLODIPINE BESYLATE
2 shared
PHARMACIA
Shared indications:
HypertensionCoronary Artery Disease
KATERZIA
AMLODIPINE BENZOATE
2 shared
AZURITY
Shared indications:
HypertensionCoronary Artery Disease
NIFEDIPINE
NIFEDIPINE
2 shared
OSMOTICA PHARM US
Shared indications:
Vasospastic AnginaChronic Stable Angina
NORVASC
AMLODIPINE BESYLATE
2 shared
Viatris
Shared indications:
HypertensionCoronary Artery Disease
PERINDOPRIL ERBUMINE
PERINDOPRIL ERBUMINE
2 shared
Aurobindo Pharma
Shared indications:
HypertensionCoronary Artery Disease
PROCARDIA
NIFEDIPINE
2 shared
Pfizer
Shared indications:
Vasospastic AnginaChronic Stable Angina
PROCARDIA XL
NIFEDIPINE
2 shared
Pfizer
Shared indications:
Vasospastic AnginaChronic Stable Angina
ACEBUTOLOL HYDROCHLORIDE
ACEBUTOLOL HYDROCHLORIDE
1 shared
AMNEAL PHARM
Shared indications:
Hypertension
ALDACTONE
SPIRONOLACTONE
1 shared
Pfizer
Shared indications:
Hypertension
ALISKIREN HEMIFUMARATE
ALISKIREN HEMIFUMARATE
1 shared
PH HEALTH
Shared indications:
Hypertension
AMILORIDE HYDROCHLORIDE
AMILORIDE HYDROCHLORIDE
1 shared
SIGMAPHARM LABS LLC
Shared indications:
Hypertension
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE
AMLODIPINE BESYLATE
1 shared
Aurobindo Pharma
Shared indications:
Hypertension
AMMONIA N 13
AMMONIA N-13
1 shared
BIOMEDCL RES FDN
Shared indications:
Coronary Artery Disease
ARBLI
LOSARTAN POTASSIUM
1 shared
SCIENTURE
Shared indications:
Hypertension
ATACAND
CANDESARTAN CILEXETIL
1 shared
ANI PHARMS
Shared indications:
Hypertension
ATACAND HCT
CANDESARTAN CILEXETIL
1 shared
ANI PHARMS
Shared indications:
Hypertension
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NORLIQVA FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

NORLIQVA is a calcium channel blocker for the treatment of: Hypertension NORLIQVA is indicated for the treatment of hypertension in adults and children 6 years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction <40% 1.1 Hypertension NORLIQVAยฎ is indicated for the trea...

NORLIQVA Patents & Exclusivity

Latest Patent: Feb 2041

Patents (18 active)

US12226528 Expires Feb 24, 2041
US11458095 Expires Feb 24, 2041
US12005141 Expires Feb 24, 2041
US12440441 Expires Feb 24, 2041
US11723866 Expires Feb 24, 2041
US11253474 Expires Feb 24, 2041
+ 8 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.